Loading
companiesCompany
Theolytics
Theolytics is an Oxford biotech that screens huge libraries of adenoviruses to find ones that kill particular cancers; THEO-260 is its lead for ovarian cancer.
Also called: Theolytics Ltd
Overview
Theolytics, spun out of the University of Oxford, uses directed evolution and high-throughput screening of adenovirus libraries to select oncolytic viruses with the best tumour selectivity and potency for a chosen cancer. THEO-260, selected against ovarian cancer cells, entered a phase 1/2 trial in platinum-resistant ovarian cancer in 2024 and is also being developed for intravenous delivery.
Headquarters
Oxford, GB
Scorecard
All companies#487of 1244 companies, score 5
- phase 1/2 +1
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Website
Phase 2Oncolytic virus
THEO-260 is an oncolytic virus from Theolytics Limited, in registered phase 2 trials for ovarian cancer.
drugs
Phase 2Oncolytic virus